TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15108829

Group type: EXPERIMENTAL
Intervention: 26-gauge Atraucan spinal needle (AT group)
Number of subjects: 215

Group type: COMPARATOR
Intervention: 25-gauge Whitacre spinal needle (WH group)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 215
Study: 11422338

Group type: EXPERIMENTAL
Intervention: Pregabalin (PGB) 50-600 mg/day
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Pregabalin (PGB)
Number of subjects: 19
Study: 9408785

Group type: EXPERIMENTAL
Intervention: Reinforcement condition (1 month's free membership)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo condition (letter by mail)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 300
Study: 8508556

Group type: EXPERIMENTAL
Intervention: Prednisone (30 mg, alternate days)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Piroxicam (20 mg, daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2950827

Group type: EXPERIMENTAL
Intervention: PDC-HDC diacetate (306.5 mg over five weeks, followed by 960 mg during maintenance)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: PDC-HDC diacetate
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 29653297

Group type: EXPERIMENTAL
Intervention: Active transcranial random noise stimulation (tRNS)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 3
Study: 27076209

Group type: EXPERIMENTAL
Intervention: Memantine (MEM) 20 mg p.o.
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 24722932

Group type: EXPERIMENTAL
Intervention: Telemonitoring (daily measuring of health parameters including ECG, blood pressure, weight, and self-assessment)
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Telemonitoring training and support
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Telemonitoring system
Number of subjects: 710
Study: 23335153

Group type: EXPERIMENTAL
Intervention: Intervention 1 (one visit)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Intervention 2 (two visits)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 298
Study: 20361391

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity
Number of subjects: 390

Group type: COMPARATOR
Intervention: Control group (A allele carriers)
Number of subjects: 390
Study: 17950982

Group type: EXPERIMENTAL
Intervention: Glucose administration (25 g)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Inert placebo drink
Number of subjects: 56
Study: 16813972

Group type: EXPERIMENTAL
Intervention: Light-protected TPN (LP)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Light-exposed TPN (LE)
Number of subjects: 37
Study: 14710772

Group type: COMPARATOR
Intervention: Mechanical tooth cleaning only (Period A)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine mouthrinse (Period B)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1.0% chlorhexidine gel (Period C)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (both Periods B and C)
Number of subjects: 10
Study: 10910607

Group type: EXPERIMENTAL
Intervention: MMR and JE vaccines nonsimultaneously (Group A)
Number of subjects: 145

Group type: COMPARATOR
Intervention: MMR and JE vaccines simultaneously (Group B)
Number of subjects: 145
Study: 7478973

Group type: EXPERIMENTAL
Intervention: Intensive one-year follow-up at a secondary prevention specialist clinic
Number of subjects: 99

Group type: COMPARATOR
Intervention: Conventional follow-up in the primary health care system
Number of subjects: 99
Study: 1699597

Group type: EXPERIMENTAL
Intervention: Cornflakes (350 g/d, providing 10.33 g RS/d)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Rice Krispies (380 g/d, providing 0.86 g RS/d)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cornflakes
Number of subjects: 8
Study: 7365045

Group type: EXPERIMENTAL
Intervention: In vivo exposure only for 2 weeks
Number of subjects: 8

Group type: COMPARATOR
Intervention: Response prevention only for 2 weeks
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combined treatment (exposure + response prevention) for 2 weeks after initial treatments
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Additional 2 weeks of exposure
Number of subjects: 8

Group type: COMPARATOR
Intervention: Additional 2 weeks of response prevention
Number of subjects: 8
Study: 29212562

Group type: EXPERIMENTAL
Intervention: (-)-OSU6162
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 27759458

Group type: EXPERIMENTAL
Intervention: Amberen dietary supplement
Number of subjects: 125
Study: 24754555

Group type: EXPERIMENTAL
Intervention: Circle of Life (COL) intervention
Number of subjects: 635

Group type: COMPARATOR
Intervention: Control group (those who did not receive COL)
Number of subjects: 635
Study: 22116416

Group type: EXPERIMENTAL
Intervention: Shunt placed with proGAV(®) adjustable valve, immediately adjusted to function (Group A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Shunt placed with proGAV(®) adjustable valve, adjusted to the highest setting for 3 months then adjusted to function (Group B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shunt placed with proGAV(®) adjustable valve (both groups)
Number of subjects: 0
Study: 20392515

Group type: EXPERIMENTAL
Intervention: Three breathlessness management training sessions
Number of subjects: 22

Group type: COMPARATOR
Intervention: Single breathlessness management training session
Number of subjects: 22
Study: 18155581

Group type: EXPERIMENTAL
Intervention: Partial matrix excision
Number of subjects: 105

Group type: COMPARATOR
Intervention: Orthonyxia
Number of subjects: 105
Study: 15964160

Group type: EXPERIMENTAL
Intervention: CEE/MPA 5 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: CEE/MPA 2.5 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tibolone 2.5 mg
Number of subjects: 100
Study: 12943974

Group type: EXPERIMENTAL
Intervention: Pyrethroid-impregnated curtains
Number of subjects: 96

Group type: COMPARATOR
Intervention: Non-impregnated curtains
Number of subjects: 96
Study: 10687548

Group type: EXPERIMENTAL
Intervention: Dynamic multisegmental surface
Number of subjects: 20

Group type: COMPARATOR
Intervention: Static surface (gel pad)
Number of subjects: 20
Study: 8681149

Group type: EXPERIMENTAL
Intervention: 5-cc saline bolus
Number of subjects: 20

Group type: COMPARATOR
Intervention: No saline bolus
Number of subjects: 20
Study: 2028354

Group type: EXPERIMENTAL
Intervention: Analgesic/anti-inflammatory combined medication (Myprodol; Rio Ethicals)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Anti-inflammatory medication (Voltaren; Geigy)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 43
Study: 7005415

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 6737407

Group type: EXPERIMENTAL
Intervention: Book-instructed
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Computer-instructed
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Therapist-instructed
Number of subjects: 71
Study: 31383825

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU/day for 2 months)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 29945272

Group type: EXPERIMENTAL
Intervention: Narrow repetition zone (NPR, n=20) with 12/10/8 repetitions
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Wide repetition zone (WPR, n=19) with 15/10/5 repetitions
Number of subjects: 39
Study: 26070923

Group type: EXPERIMENTAL
Intervention: Bonded expander and facial mask (FM)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Banded expander and facial mask (FM)
Number of subjects: 50
Study: 25010364

Group type: EXPERIMENTAL
Intervention: Ultrasound using speckle tracking
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Ultrasound using M mode
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Pleural elastance (PEL)
Number of subjects: 81
Study: 21638147

Group type: EXPERIMENTAL
Intervention: NBCA (Histoacryl, Braun, Germany)
Number of subjects: 83

Group type: COMPARATOR
Intervention: NBCA‐MS (Glubran2, General Enterprise Marketing, Viareggio, Lucca, Italy)
Number of subjects: 83
Study: 20113764

Group type: EXPERIMENTAL
Intervention: Palpation Meter (PALM)
Number of subjects: 30
Study: 18554204

Group type: EXPERIMENTAL
Intervention: AFL ablation
Number of subjects: 137

Group type: COMPARATOR
Intervention: Medical therapy (control)
Number of subjects: 137
Study: 16154735

Group type: EXPERIMENTAL
Intervention: Regular intermittent epidural boluses (5 mL every half hour)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continuous epidural infusion of levobupivacaine 0.1% with fentanyl 2 microg/mL at a rate of 10 mL/h
Number of subjects: 60
Study: 12094341

Group type: EXPERIMENTAL
Intervention: Gemcitabine/cisplatin combination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Number of subjects: 0
Study: 10421644

Group type: EXPERIMENTAL
Intervention: Somatostatin (SMT) infusion (250 micrograms/h) for 5 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Somatostatin (SMT) infusion (250 micrograms/h) for 5 days + sclerotherapy
Number of subjects: 100
Study: 7804963

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) chemotherapy
Number of subjects: 331
Study: 2316838

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 7352851

Group type: EXPERIMENTAL
Intervention: Trihexyphenidyl hydrochloride
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 31852096

Group type: EXPERIMENTAL
Intervention: Triglyceride glucose (TyG) index
Number of subjects: 26093
Study: 28893757

Group type: EXPERIMENTAL
Intervention: Duloxetine and usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 0
Study: 27059729

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily for 12 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 25538468

Group type: EXPERIMENTAL
Intervention: Chlorhexidine varnish after scaling and root planing (SRP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gel after scaling and root planing (SRP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 30
Study: 22545741

Group type: EXPERIMENTAL
Intervention: Acceptance training (enhanced through video format and guided experiential exercise)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no acceptance training)
Number of subjects: 100
Study: 19393887

Group type: EXPERIMENTAL
Intervention: 1.8 mm microcoaxial cataract surgery system
Number of subjects: 78

Group type: COMPARATOR
Intervention: 2.2 mm microcoaxial cataract surgery system
Number of subjects: 78
Study: 17601461

Group type: EXPERIMENTAL
Intervention: High-intensity FES-ET (1 hour a day for 15 to 20 consecutive workdays)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Low-intensity FES-ET (15 minutes of sensory electric stimulation 4 days a week, 1 hour of FES-ET on the fifth day)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: High-intensity FES-ET
Number of subjects: 19

Group type: COMPARATOR
Intervention: Low-intensity FES-ET
Number of subjects: 19
Study: 15684796

Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated)
Number of subjects: 474

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 474
Study: 10928571

Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pergolide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study: 9107585

Group type: EXPERIMENTAL
Intervention: Browne Pneumatic Impactor (BPI)
Number of subjects: 9
Study: 8450326

Group type: EXPERIMENTAL
Intervention: Nicardipine (0.15 mg/kg/hr by continuous infusion for up to 14 days)
Number of subjects: 906

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 906
Study: 3828486

Group type: EXPERIMENTAL
Intervention: pH 2.3 solution of 0.5 mg triazolam
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: pH 6.0 solution of 0.5 mg triazolam
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: pH 6.0 solution of 0.5 mg triazolam during cimetidine treatment (1200 mg day-1)
Number of subjects: 4
Study: 30957525

Group type: EXPERIMENTAL
Intervention: Cognitive‐Behavioral Therapy‐based integrated treatment/management program (active treatment condition)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 27
Study: 27126198

Group type: EXPERIMENTAL
Intervention: 54 mg genistein daily for 1 year
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 25519790

Group type: EXPERIMENTAL
Intervention: Early initiation of antiretroviral therapy (ART) within 2 weeks
Number of subjects: 816

Group type: COMPARATOR
Intervention: Deferred initiation of antiretroviral therapy (ART) starting a median of 1.3 years after enrollment
Number of subjects: 816

Group type: COMPARATOR
Intervention: Deferred treatment group
Number of subjects: 816
Study: 23423316

Group type: EXPERIMENTAL
Intervention: Early start OKC exercises (EOKC) starting at the fourth week postoperatively within a restricted ROM (45° to 90°)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Late start OKC exercises (LOKC) starting at the 12th week postoperatively within a restricted ROM (0° to 90°)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both EOKC and LOKC groups
Number of subjects: 49
Study: 21515846

Group type: EXPERIMENTAL
Intervention: ramipril
Number of subjects: 3366

Group type: EXPERIMENTAL
Intervention: rosiglitazone
Number of subjects: 3366

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 3366
Study: 18320302

Group type: EXPERIMENTAL
Intervention: Anger expression intervention (n=51)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (non-emotional writing, n=51)
Number of subjects: 102
Study: 17059439

Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 90

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 90

Group type: COMPARATOR
Intervention: Physical training
Number of subjects: 90
Study: 12632024

Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin (280 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (no aprotinin)
Number of subjects: 120
Study: 10692268

Group type: EXPERIMENTAL
Intervention: Amlodipine (mean dose, 9 mg/d)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Enalapril (mean dose, 17 mg/d)
Number of subjects: 24
Study: 9441387

Group type: EXPERIMENTAL
Intervention: Paedamin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Vaminolac
Number of subjects: 20
Study: 8225688

Group type: EXPERIMENTAL
Intervention: Nocloprost (200 micrograms) given twice daily for 8 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3949999

Group type: EXPERIMENTAL
Intervention: Judges with only the label 'clinical depression'
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Judges with an extensive definition of 'clinical depression'
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Judges with both conditions (label and extensive definition)
Number of subjects: 56
Study: 31248676

Group type: EXPERIMENTAL
Intervention: Epinephrine dosing interval less than 3 minutes
Number of subjects: 15909

Group type: COMPARATOR
Intervention: Epinephrine dosing interval 3 to less than 4 minutes
Number of subjects: 15909

Group type: COMPARATOR
Intervention: Epinephrine dosing interval 4 to less than 5 minutes
Number of subjects: 15909

Group type: COMPARATOR
Intervention: Epinephrine dosing interval greater than or equal to 5 minutes
Number of subjects: 15909
Study: 28776276

Group type: EXPERIMENTAL
Intervention: High cash transfer
Number of subjects: 988

Group type: EXPERIMENTAL
Intervention: Low cash transfer
Number of subjects: 988

Group type: COMPARATOR
Intervention: No cash control
Number of subjects: 988
Study: 28122366

Group type: EXPERIMENTAL
Intervention: Comprehensive, Individualized, Person-Centered Management (CI-PCM) program
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual community care (Control)
Number of subjects: 20
Study: 25425373

Group type: COMPARATOR
Intervention: Standard arm - cervix visualized, no prespecified cervical length measurement
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sequential arm - 3 transabdominal cervical length measurements obtained, transvaginal sonography performed if images were inadequate or if any measurement was 3 cm or less
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Screening transvaginal sonography arm - 3 transvaginal cervical length measurements obtained
Number of subjects: 60
Study: 23719016

Group type: EXPERIMENTAL
Intervention: Fuji VII
Number of subjects: 57

Group type: COMPARATOR
Intervention: Concise
Number of subjects: 57
Study: 20809722

Group type: EXPERIMENTAL
Intervention: Prestige disc prosthesis
Number of subjects: 541

Group type: COMPARATOR
Intervention: Instrumented interbody fusion (Control)
Number of subjects: 541
Study: 18394126

Group type: EXPERIMENTAL
Intervention: Methacholine (MCh)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Adenosine 5'-monophosphate (AMP)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Methacholine (MCh) and Adenosine 5'-monophosphate (AMP)
Number of subjects: 113
Study: 16608131

Group type: EXPERIMENTAL
Intervention: Tai Chi (TC) training
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control training
Number of subjects: 22
Study: 14696412

Group type: EXPERIMENTAL
Intervention: General anesthesia plus epidural anesthesia and analgesia (Group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: General anesthesia with postoperative i.v. analgesia (Group B)
Number of subjects: 50
Study: 11095259

Group type: EXPERIMENTAL
Intervention: Magnetic endoscope imaging (MEI) view
Number of subjects: 296

Group type: COMPARATOR
Intervention: No imager view (Control)
Number of subjects: 296
Study: 8151462

Group type: EXPERIMENTAL
Intervention: Ceftriaxone, 50 mg/kg intramuscularly
Number of subjects: 6733

Group type: COMPARATOR
Intervention: Amoxicillin, 20 mg/kg/dose orally for six doses
Number of subjects: 6733

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 6733

Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 6733
Study: 3048273

Group type: EXPERIMENTAL
Intervention: Cardiovascular fitness training (CVR)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Flexibility exercises (FLEX)
Number of subjects: 42
Study: 29183095

Group type: EXPERIMENTAL
Intervention: Uterine artery volumetric flow
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Uterine artery resistance index (RI)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Smoking status
Number of subjects: 61
Study: 28687178

Group type: EXPERIMENTAL
Intervention: Exposed to mandated abortion counseling via a standardized video
Number of subjects: 46

Group type: COMPARATOR
Intervention: Unexposed to mandated abortion counseling
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Controlling for participant income category
Number of subjects: 46
Study: 29258980

Group type: EXPERIMENTAL
Intervention: Blended care self-management program 'Partner in Balance' (PiB) combining face-to-face coaching with tailored web-based modules.
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Blended care self-management program 'Partner in Balance' (PiB)
Number of subjects: 49
Study: 23715625

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg
Number of subjects: 643

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 643
Study: 21935965

Group type: EXPERIMENTAL
Intervention: Modified-release zaleplon 15 mg (SKP-1041A, SKP-1041B, SKP-1041C)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Modified-release zaleplon 15 mg (SKP-1041A, SKP-1041B)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Immediate-release zaleplon 10 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Modified-release zaleplon 15 mg (SKP-1041)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: SKP-1041B
Number of subjects: 42
Study: 20205026

Group type: EXPERIMENTAL
Intervention: pedometer and pretest (n = 16)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: pedometer and no pretest (n = 16)
Number of subjects: 63

Group type: COMPARATOR
Intervention: no pedometer and pretest (n = 15)
Number of subjects: 63

Group type: COMPARATOR
Intervention: no pedometer and no pretest (n = 16)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: pedometer use
Number of subjects: 63
Study: 17354160

Group type: EXPERIMENTAL
Intervention: Pivmecillinam (various regimens)
Number of subjects: 884

Group type: EXPERIMENTAL
Intervention: Pivmecillinam 3 days regimen
Number of subjects: 884

Group type: EXPERIMENTAL
Intervention: Pivmecillinam 7 days regimen
Number of subjects: 884

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 884
Study: 15279475

Group type: EXPERIMENTAL
Intervention: OptiBond FL combined with Prodigy (O-FL/Pro)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: PermaQuick combined with Amelogen Hybrid (PMQ/A-Hy)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: PermaQuick combined with Amelogen Microfill (PMQ/A-Mi)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Comparison of microfilled and hybrid composites
Number of subjects: 150
Study: 11529537

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (GH) at a dose of 0.15 IU kg(-1) per day for 3 years (Group A: discontinuous, Group B: control for 1 year then continuous, Group C: continuous)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Growth hormone treatment (GH) (Group A: discontinuous, Group B: continuous after 1 year, Group C: continuous)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (GH) (Group A: discontinuous, Group B: continuous, Group C: continuous)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (GH) (Group A: discontinuous)
Number of subjects: 37
Study: 9555791

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid-based lipid emulsion (Omegavenous; 200 ml/day with 4.2 gm of both EPA and DHA)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Conventional omega-6-lipid emulsion (Lipovenous; EPA+DHA < 0.1 gm/100 ml)
Number of subjects: 83
Study: 7602351

Group type: EXPERIMENTAL
Intervention: r‐Hu‐EPO 150 IU/kg three times per week
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: r‐Hu‐EPO 300 IU/kg three times per week
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no r‐Hu‐EPO)
Number of subjects: 36